175 related articles for article (PubMed ID: 11894734)
1. Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine.
Lytinas M; Kempuraj D; Huang M; Kandere K; Boucher W; Letourneau R; Jeudy S; Fitzgerald K; Spear K; Athanasiou A; Theoharides TC
Allergy Asthma Proc; 2002; 23(1):45-51. PubMed ID: 11894734
[TBL] [Abstract][Full Text] [Related]
2. Azelastine is more potent than olopatadine n inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells.
Kempuraj D; Huang M; Kandere K; Boucher W; Letourneau R; Jeudy S; Fitzgerald K; Spear K; Athanasiou A; Theoharides TC
Ann Allergy Asthma Immunol; 2002 May; 88(5):501-6. PubMed ID: 12027072
[TBL] [Abstract][Full Text] [Related]
3. Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists.
Lytinas M; Kempuraj D; Huang M; Boucher W; Esposito P; Theoharides TC
Int Arch Allergy Immunol; 2003 Mar; 130(3):224-31. PubMed ID: 12660427
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
Sharif NA; Xu SX; Miller ST; Gamache DA; Yanni JM
J Pharmacol Exp Ther; 1996 Sep; 278(3):1252-61. PubMed ID: 8819509
[TBL] [Abstract][Full Text] [Related]
5. Interactions of olopatadine and selected antihistamines with model and natural membranes.
Brockman HL; Momsen MM; Knudtson JR; Miller ST; Graff G; Yanni JM
Ocul Immunol Inflamm; 2003 Dec; 11(4):247-68. PubMed ID: 14704897
[TBL] [Abstract][Full Text] [Related]
6. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
Yanni JM; Stephens DJ; Miller ST; Weimer LK; Graff G; Parnell D; Lang LS; Spellman JM; Brady MT; Gamache DA
J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675
[TBL] [Abstract][Full Text] [Related]
7. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells.
Cook EB; Stahl JL; Barney NP; Graziano FM
Ann Allergy Asthma Immunol; 2001 Nov; 87(5):424-9. PubMed ID: 11730187
[TBL] [Abstract][Full Text] [Related]
8. Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells.
Kempuraj D; Huang M; Kandere-Grzybowska K; Basu S; Boucher W; Letourneau R; Athanassiou A; Theoharides TC
Int Arch Allergy Immunol; 2003 Nov; 132(3):231-9. PubMed ID: 14646384
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells.
Yanni JM; Miller ST; Gamache DA; Spellman JM; Xu S; Sharif NA
Ann Allergy Asthma Immunol; 1997 Dec; 79(6):541-5. PubMed ID: 9433371
[TBL] [Abstract][Full Text] [Related]
10. Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability.
Beauregard C; Stephens D; Roberts L; Gamache D; Yanni J
J Ocul Pharmacol Ther; 2007 Aug; 23(4):315-20. PubMed ID: 17803429
[TBL] [Abstract][Full Text] [Related]
11. Human mast cell tryptase: a stimulus of microvascular leakage and mast cell activation.
He S; Walls AF
Eur J Pharmacol; 1997 Jun; 328(1):89-97. PubMed ID: 9203574
[TBL] [Abstract][Full Text] [Related]
12. Olopatadine inhibits exocytosis in rat peritoneal mast cells by counteracting membrane surface deformation.
Baba A; Tachi M; Maruyama Y; Kazama I
Cell Physiol Biochem; 2015; 35(1):386-96. PubMed ID: 25591779
[TBL] [Abstract][Full Text] [Related]
13. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects.
Theoharides TC; Singh LK; Boucher W; Pang X; Letourneau R; Webster E; Chrousos G
Endocrinology; 1998 Jan; 139(1):403-13. PubMed ID: 9421440
[TBL] [Abstract][Full Text] [Related]
14. Olopatadine inhibits TNFalpha release from human conjunctival mast cells.
Cook EB; Stahl JL; Barney NP; Graziano FM
Ann Allergy Asthma Immunol; 2000 May; 84(5):504-8. PubMed ID: 10831003
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
Spangler DL; Bensch G; Berdy GJ
Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
[TBL] [Abstract][Full Text] [Related]
16. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
Galatowicz G; Ajayi Y; Stern ME; Calder VL
Clin Exp Allergy; 2007 Nov; 37(11):1648-56. PubMed ID: 17877767
[TBL] [Abstract][Full Text] [Related]
17. Effects of olopatadine hydrochloride on the cutaneous vascular hyperpermeability and the scratching behavior induced by poly-L-arginine in rats.
Hayashi K; Kaise T; Ohmori K; Ishii A; Karasawa A
Jpn J Pharmacol; 2001 Oct; 87(2):167-70. PubMed ID: 11700017
[TBL] [Abstract][Full Text] [Related]
18. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
Rosenwasser LJ; O'Brien T; Weyne J
Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
[TBL] [Abstract][Full Text] [Related]
19. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
Kida T; Fujii A; Sakai O; Iemura M; Atsumi I; Wada T; Sakaki H
Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
[TBL] [Abstract][Full Text] [Related]
20. Suppression of TNF-alpha secretion by azelastine in a rat mast (RBL-2H3) cell line: evidence for differential regulation of TNF-alpha release, transcription, and degranulation.
Hide I; Toriu N; Nuibe T; Inoue A; Hide M; Yamamoto S; Nakata Y
J Immunol; 1997 Sep; 159(6):2932-40. PubMed ID: 9300717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
